Alcohol use disorder (AUD).
Conditions
Brief summary
Percent heavy drinking days (HDD) as assessed using Timeline Followback interview.
Detailed description
Number of standard unit drinks as assessed using Timeline Followback interview., Percent of days drinking (PDD) as assessed using Timeline Followback interview., WHO Risk Level of alcohol consumption as assessed using Timelines Followback interview.
Interventions
DRUGSunobinop 0.5 mg
DRUGSunobinop 2 mg
DRUGSunobinop 1 mg
DRUGV117957 Tablets Placebo - The placebo formulation has the same qualitative composition as the corresponding active formulation of V117957 Tablets
DRUGwith the absence of the API. The only difference in the dosage forms of V117957 Tablets and the placebo are that V117957 is replaced in the placebo tablet with an additional amount of microcrystalline cellulose.
Sponsors
Imbrium Therapeutics LP
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent heavy drinking days (HDD) as assessed using Timeline Followback interview. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of standard unit drinks as assessed using Timeline Followback interview., Percent of days drinking (PDD) as assessed using Timeline Followback interview., WHO Risk Level of alcohol consumption as assessed using Timelines Followback interview. | — |
Countries
Romania
Outcome results
None listed